absoluteantibody/Anti-CD86 [PO.3]/200 μg/Ab01029-2.0

UniProt Accession Number of Target Protein: P42082

Alternative Name(s) of Target: B7-2; PO3; Activation B7-2 antigen; B-lymphocyte activation antigen B7-2; B-lymphocyte antigen B7-2; B7.2; CD28 antigen ligand 2; CD28LG2; CD86; early T cell costimulatory molecule-1; early T-cell costimulatory molecule 1; ETC-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86Immunogen: This antibody was raised by immunising Sprague Dawley rats with a mouse B cell line, BCL1 and fusing immune splenocytes with P3U1 myeloma cells.

Specificity: This antibody is specific for murine CD86, an ~80 kDa surface receptor of the B7 family of costimulatory molecules. In addition to CD80, CD86 is a counter-receptor for the T cell surface molecules CD28 and CD152 (CTLA-4). This interaction plays a critical role in T-B crosstalk, T cell costimulation, autoantibody production and Th2-mediated Ig production.

Application Notes: This antibody has been used in multiple FACS experiments for various immunological applications, such as to demonstrate how the C-type lectin receptor DCIR modulates immunity to tuberculosis (Troegeler et al, 2017), to elucidate the mechanism of Th17 cell differentiation by cholera toxin (Kang et al, 2016), and to evaluate the role of the spleen tyrosine kinase in graft-versus-host disease (Flynn et al, 2015). This antibody has also been used in immunofluorescence to investigate the potential of peritoneal cavity B cells to alleviate murine colitis (Maseda et al, 2013), and in Western Blot to study the effect of interleukin 4-induced gene-1 (IL4I1) overexpression on the expression of M2 markers and M1-associated cytokines (Yue et al, 2015). Furthermore, this antibody has been used, together with the anti-CD80 antibody, in numerous in vivo studies, such as in a NZB/W F1 mouse lupus model to clarify the role of CD80 and CD86 in murine Ab-mediated autoimmunity (Nakajima et al, 1995), in graft bearing recipient BALB/c mice to evaluate the roles of CD80 and CD86 costimulatory molecules in corneal allograft rejection (Kagaya et al, 2002), and in transgenic BALB/c mice to demonstrate the critical contribution of CD80 and CD86 in anterior chamber-associated immune deviation (Tsukahara et al, 2005).

Antibody first published in:Atsuo Nakajima et al.Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory moleculEur J Immunol. 1995 Nov;25(11):3060-9.PMID:7489744Note on publication:Describe the use of this antibody, together with the anti-CD80 antibody, to confirm the preferential dependence of murine Ab-mediated autoimmunity on the CD86 costimulatory molecule.